Cerliponase Alfa

Cerliponase Alfa is a recombinant form of human tripeptidyl peptidase 1 (TPP1) enzyme used for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a rare and fatal lysosomal storage disorder in children. It is administered directly into the cerebrospinal fluid via intraventricular infusion. Mediocon Inc supplies pharmaceutical-grade Cerliponase Alfa API for biopharmaceutical manufacturers.

Key Features

• Recombinant TPP1 enzyme replacement
• IP/BP/EP/USP compliant quality
• Treats CLN2 (Batten disease variant)
• Intraventricular CSF administration

Applications

• CLN2 neuronal ceroid lipofuscinosis treatment
• Rare pediatric neurology
• Intraventricular enzyme infusion
• Biopharmaceutical formulation

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings